Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMKBTFG)

Drug Name
Cefozopran Drug Info
Synonyms
CZOP; Cefozopran [INN]; SCE 2787; Cefozopran (INN); (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt
Cross-matching ID
PubChem CID
9571080
ChEBI ID
CHEMBL3502
CAS Number
CAS 113359-04-9
TTD Drug ID
D0B5FZ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.22 0.00e+0 34/36 (94.44%) PCNA;MCM4;POLE2;...
Drug metabolism 1.83 4.75e-2 78/151 (51.66%) ADH5;MPO;GSTA1;...
Hypertrophic cardiomyopathy -1.72 4.99e-2 81/90 (90%) TPM1;ITGA9;ITGA5;...
Rheumatoid arthritis -1.73 4.51e-2 78/93 (83.87%) HLA-DMB;TNFRSF11A;HLA-DOB;...
Valine, leucine and isoleucine degradation -1.73 4.93e-2 42/48 (87.5%) BCAT1;ACAA1;HSD17B10;...
IL-17 signaling pathway -1.75 3.81e-2 84/94 (89.36%) MMP9;DEFB4A;TNF;...
Amoebiasis -1.77 3.67e-2 99/102 (97.06%) CD1C;COL4A3;CD1A;...
Primary immunodeficiency -1.78 3.48e-2 33/38 (86.84%) CD40LG;TNFRSF13B;ICOS;...
Steroid hormone biosynthesis -1.80 3.48e-2 43/61 (70.49%) STS;HSD3B1;CYP11B1;...
Pancreatic secretion -1.90 3.87e-3 87/102 (85.29%) RAP1B;ATP1A2;ATP1B3;...
Hematopoietic cell lineage -1.90 5.80e-3 90/99 (90.91%) HLA-DMB;FCER2;ITGA6;...
Bladder cancer -2.07 0.00e+0 40/41 (97.56%) DAPK3;MMP9;MAP2K2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H